Recent

% | $
Quotes you view appear here for quick access.

Pharmacyclics, Inc. Message Board

  • maxcoatinc maxcoatinc Jun 10, 2013 2:18 PM Flag

    18th European Hematology Conference starts end of this week - Expect some price gains

    I expect that PCYC held something back from ASCO at the request of Janssen

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • European Hematology Association 18th Congress in Stockholm, Sweden June 13-16, 2013

      At the European Hematology Association (EHA) annual congress there will be four presentations; two oral and two poster presentations. The oral presentations will be from the clinical trials PCYC-1106, Pharmacyclics' Phase II study using ibrutinib as a monotherapy in patients with relapsed or refractory (R/R) ABC sub-type of diffuse large B-cell lymphoma (DLBCL) and from PCYC-1104, Pharmacyclics' Phase II study using ibrutinib as a monotherapy in R/R mantle cell lymphoma (MCL) patients. Pharmacyclics will also present non-clinical data in a poster presentation on BTK expression in multiple myeloma (MM). There will also be a poster presentation discussing the Phase I study of ibrutinib combined with R-CHOP in frontline NHL patients as reported previously at ASCO in June, 2013.

      Oral Presentation
      The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), has Preferential Activity in the Activated B-cell-like (ABC) Subtype of Relapsed/Refractory (R/R) DLBCL: Interim Phase 2 Results Date/Time: June 16, 2013, 11:30AM-11:45AM, Location: Hall A7, Author: Dr. Sven de Vos
      Oral Presentation
      Updated Interim Results of an International, Multicenter, Phase 2 Study of Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma
      Date/Time: June 16, 2013, 11:00AM-11:15AM, Location: Hall A7, Author: Dr. Simon Rule
      Poster Presentation
      Bruton Tyrosine Kinase Expression in Multiple Myeloma
      Date/Time: June 14, 2013, 5:45PM-7:00PM, Location: Poster Hall, Author: Dr. Laurence Elias
      Poster Presentation (Encore from ASCO)
      Phase 1b Study Combining Ibrutinib with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Patients with CD20-Positive B-Cell Non-Hodgkin Lymphoma (NHL)
      Date/Time: June 15, 2013, 5:45PM-7:00PM, Location: Poster Hall, Author: Dr. Anas Younes
      International Conference on Malignant Lymphoma in Lugano, Switzerland

      Sentiment: Strong Buy

      • 2 Replies to jgmtruth
      • Results: BTK mRNA was over-expressed in most MM patient samples (74.1%), which was similar to CLL (79.2%), or B cell lymphomas (91-100 %), and to a much greater extent than seen in any solid tumor grouping. In comparison with MM, trends towards a higher level of expression were observed in cases of MGUS subtype (92.7%, N= 57) and in plasma cell leukemia (91.7%, N=12). Previously treated patient samples had a slightly greater incidence of over-expression (82.8%, N=842). No differences however were identified between patients with ISS stages I, II or III, patients with or without hyper-diploid cytogenetics, or in patients with light chain myeloma vs IgA/IgG myeloma. BTK was broadly expressed across molecular and cytogenetic subgroupings, however patients with gains of chromosome 11 or CCND1 amplification tended to have higher levels of BTK expression, whereas samples from patients in the MS (Zhan et al, Blood 2006;108:2020-2028) or TC 4 (Agnelli et al, J Clin Oncol 2005;23:7296-7306) molecular subgroups (generally associated with t(4;14) and related abnormalities) had lower BTK expression, as compared to other subgroups. BTK over-expression was similarly seen to correlate inversely with FGFR3 expression (characteristic of t(4;14)). BTK further showed some degree of co-expression with BCR associated B cell determinants such as CD79a, CD79b, and SYK; a correlation with CXCR4 was also noted.

      • Oral Presentation
        Updated Interim Results of an International, Multicenter, Phase 2 Study of Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma
        Date/Time: June 16, 2013, 11:00AM-11:15AM, Location: Hall A7, Author: Dr. Simon Rule

        Sentiment: Strong Buy

 
PCYC
257.100.00(0.00%)Apr 23 3:59 PMEDT